Xynomic Pharmaceuticals, Inc.
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT05275374
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04024696
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, China
🇨🇳The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT03936153
- Locations
- 🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, China
🇨🇳The First Affiliate Hospital of Dalian Medical University, Dalian, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT03934567
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳China-Japan Friendship Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT03600441
- Locations
- 🇫🇷
Centre Hospitalier de Perpignan, Perpignan, Pyrénées-Orientales, France
🇪🇸C.H. Regional Reina Sofia, Córdoba, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- Conditions
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 413
- Registration Number
- NCT03592472
- Locations
- 🇪🇸
H.U. Virgen de la Victoria, Málaga, Spain
🇪🇸H.G.U. de Elche, Elche, Spain
🇪🇸Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain